Adult Brainstem Gliomas

Reyes‐Botero, Germán; Mokhtari, Karima; Martin-Duverneuil, N; Delattre, Jean‐Yves; Laigle‐Donadey, Florence

doi:10.1634/theoncologist.2011-0335

Cited by 83 publications

(78 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As compared to childhood brainstem glioma the average survival time in adults is as high as 5 years [1]. The first choice of treatment in brainstem gliomas is radiotherapy [1]. In this case, a 28-year-old female was diagnosed with brainstem glioma as lesion identified in pons and medulla of the brain stem.…”

Section: Discussionmentioning

confidence: 92%

“…Because of the augmented growth rate, symptoms of high-grade pontine gliomas are usually short in duration and rapidly progressive [6]. As compared to childhood brainstem glioma the average survival time in adults is as high as 5 years [1]. The first choice of treatment in brainstem gliomas is radiotherapy [1].…”

Section: Discussionmentioning

confidence: 99%

“…Magnetic resonance imaging (MRI) is widely used tool for diagnosis of brainstem glioma as biopsies are rarely performed in brainstem tumours [1].…”

Section: Introductionmentioning

confidence: 99%

“…Conventional radiotherapy is the standard treatment for diffuse intrinsic low-grade brainstem gliomas in adults (the median survival is 5 years) [4]. Usually all brainstem gliomas respond to radiotherapy as decided by the mitigation of neurological symptoms and evidence for improved duration of survival in patients given higher doses (> 50 Gy v < 50 Gy) of radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…Usually all brainstem gliomas respond to radiotherapy as decided by the mitigation of neurological symptoms and evidence for improved duration of survival in patients given higher doses (> 50 Gy v < 50 Gy) of radiotherapy. However, the potential advantage of combination treatment of radiotherapy and chemotherapy is not entirely evaluated in adult patients [1].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Nimotuzumab in Management of Brain Stem Glioma: A Case Report

Kumar¹,

Selvakumar²,

Rathinam³

2017

JCT

View full text Add to dashboard Cite

Brainstem glioma is rare tumour in adults accounting for 1% -2% of intracranial gliomas. In this case study, a 28-year-old female diagnosed with BG, and lesions were observed in the pons and medulla region of the brain stem. She was initially treated with radiotherapy (54 Gy in 30 fractions for 6 weeks) but no change in her clinical condition and size of tumor was observed. Temozolomide (250 mg/daily for 5 days) was prescribed as first line chemotherapy. After completion of three cycles of Temozolomide, patient presented with diplopia and MRI showed increase in the size of lesions. After unsatisfactory response to radiation and chemotherapy, the patient was treated with Nimotuzumab therapy. MRI scan demonstrated the reduction of lesion size after 8 cycles of Nimotuzumab (200 mg/week). This treatment continued for another 8 cycles and the MRI scan of patients showed a significant reduction in lesion size. Nimotuzumab was found to be an effective and safe treatment option for brainstem glioma patient who was resistant to radiotherapy and chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 92%